经皮影像引导活检诊断肝内胆管癌的效能
回顾性分析2006—2019年112例肝内胆管癌(IHCCA)患者的经皮活检资料,并与100例>1 cm的局灶性肝病变对照。IHCCA首次活检的非诊断率或与影像不一致率为16%,显著高于对照组的3.3%,最终诊断时间也显著延长;即使靶病灶更大,IHCCA首次活检诊断效能仍较低。若活检结果与影像不符,应建议及时重复活检以避免诊断延迟。
要点
- IHCCA首次经皮活检有16%结果不一致或不确定,需重复活检。
- 对照局灶性肝病变非诊断率仅3.3%,IHCCA诊断效能显著更低。
- 活检与影像不符时,应建议及时重复活检以防诊断延迟。
核心结论
- IHCCA首次经皮活检诊断效能低于其他局灶性肝病变,尽管靶病灶更大;活检结果与影像不一致时应建议及时重复活检。
研究设计与样本
- 回顾性研究,纳入2006—2019年112例IHCCA患者(54女/58男,平均62.9岁,27例肝硬化)和100例连续对照(56女/44男,平均63岁,5例肝硬化,局灶性肝病变>1 cm)。
- IHCCA平均病灶大小6.1±3.6 cm,78%取样主病灶、22%取样卫星灶;95%为超声引导,96%为粗针活检(91%为18G),中位2针。
诊断标准与关键数值
- IHCCA首次活检后18例(16%)病理结果不一致或不确定,需重复活检,其中2例共尝试3—4次;对照非诊断率3.3%,两者差异有统计学意义(P=0.001)。
- IHCCA从首次活检到最终诊断平均60±120天,对照平均21±28.8天,差异有统计学意义(P=0.002)。
- IHCCA活检轻微并发症发生率4.4%。
临床应用与阅片要点
- 对影像怀疑IHCCA的病灶,若首次活检结果与影像不一致或不确定,应建议及时重复活检,避免诊断延迟。
- IHCCA活检以超声引导粗针(常用18G,中位2针)为主,取样时需注意主病灶与卫星灶的选择。
局限性
- 回顾性研究,单中心,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the efficacy of percutaneous biopsy for diagnosing intrahepatic cholangiocarcinoma (IHCCA).
METHODS: Retrospective review of biopsy and pathology databases from 2006 to 2019 yielded 112 patients (54F/58 M; mean age, 62.9 years; 27 cirrhotic) with IHCCA who underwent percutaneous biopsy. Data regarding the lesion, biopsy procedure technique, and diagnostic yield were collected. If biopsy was non-diagnostic or discordant with imaging, details of repeat biopsy or resection/explant were gathered. A control group of 100 consecutive patients (56F/44 M; mean age, 63 years, 5 cirrhotic) with focal liver lesions > 1 cm was similarly assessed.
RESULTS: Mean IHCCA lesion size was 6.1 ± 3.6 cm, with dominant lesion sampled in 78% (vs. satellite in 22%). 95% (n = 106) were US guided and 96% were core biopsies (n = 108), typically 18G (n = 102, 91%), median 2 passes. 18 patients (16%) had discordant/ambiguous pathology results requiring repeat biopsy, with two patients requiring 3-4 total attempts. A 4.4% minor complication rate was seen. Mean time from initial biopsy to final diagnosis was 60 ± 120 days. Control group had mean lesion size of 2.9 ± 2.5 cm and showed a non-diagnostic rate of 3.3%, both significantly lower than that seen with CCA, with average time to diagnosis of 21 ± 28.8 days (p = 0.002, p = 0.001).
CONCLUSION: IHCCA is associated with lower diagnostic yield at initial percutaneous biopsy, despite larger target lesion size. If a suspicious lesion yields a biopsy result discordant with imaging, the radiologist should recommend prompt repeat biopsy to prevent delay in diagnosis.
引用
- Lubner MG, Larison WG, Watson R, et al. Efficacy of percutaneous image-guided biopsy for diagnosis of intrahepatic cholangiocarcinoma. Abdom Radiol (NY). 2021. PMID: 34687328. doi:10.1007/s00261-021-03278-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。